PRIMARY PERITONEAL CANCER

This study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…

This study is for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific genetic feature (HRD). The trial tests whether taking a combination of two drugs (a PARP inhibitor and an angiogenesis inhibitor) after initial treatment can help keep…

This study tests whether adding the experimental drug TORL-1-23 to standard chemotherapy before surgery can improve outcomes for women with advanced ovarian cancer. About 60 participants with stage III or IV disease will receive the combination, then undergo surgery to remove rem…

This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better reduce cancer before surgery in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly as…

This study tests whether a cancer-killing virus (Olvi-Vec) given into the abdomen can make platinum-resistant ovarian cancer respond to chemotherapy again. About 186 women whose cancer has not responded to at least three prior treatments will receive either Olvi-Vec plus chemo an…

This study tests an experimental drug, REGN5668, alone or with other immune-boosting medicines in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to find the safest dose and see if the combination shrinks tumors. About 612 adults whose cancer …

This study tests a new drug combination (carboplatin plus mirvetuximab soravtansine) given before surgery to people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific protein (FRα). The goal is to see if the treatment shrinks tumors enough to improve …

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This study tests an experimental drug called ART0380 in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with other chemotherapy drugs like gemcitabine or irinotecan. About 442 participants wi…

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 adults who have already had two rounds of chemotherapy will…

This study tests an experimental drug called ubamatamab, alone or with other cancer drugs, in people with advanced ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see how safe and effective these combinations are. About 220 participants w…

This study is for people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific marker called folate receptor alpha. Participants will receive a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab) before and after surgery. The goa…

This early-phase study tests a new two-drug combination (Cirtuvivint and Olaparib) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. About 50 participants will take the pills at different schedules to find the safest do…

This phase 3 trial tests whether the experimental drug BL-B01D1 works better than standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. About 384 adults who have had 1-3 prior treatment…

This study tests a supportive telehealth program called REVITALIZE to see if it can reduce how much fatigue interferes with daily life for adults with advanced ovarian cancer who are taking PARP inhibitor maintenance therapy. About 240 participants will either receive the REVITAL…

This study follows 1,000 women newly diagnosed with ovarian, fallopian tube, or primary peritoneal cancer to see how their genes (BRCA and HRD) affect their response to standard chemotherapy and surgery. Researchers will track treatment outcomes, including how much cancer is remo…